Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G Pharma Keeps Low Profile In Reorganization; Squeezes In With Charmin

Executive Summary

Procter & Gamble has ambitious plans for growing its health care business - but the role for its prescription drugs business is likely to remain decidedly low-key

You may also be interested in...

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?

Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid

P&G Taps Lafley To Turn "Tide" In Earnings: Pepper Returns As Chairman

Procter & Gamble CEO-elect A.G. Lafley will inherit the task of settling the appropriate size for P&G's investment in the pharmaceutical business.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts